Literature DB >> 9449255

Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice.

T Fukuoka1, H Kawada, A Kitayama, T Koga, M Kubota, T Harasaki, Y Kamai, S Ohya, H Yasuda, M Iwata, S Kuwahara.   

Abstract

The efficacy of CS-834, a novel oral carbapenem, was assessed by using a murine model of pneumonia caused by penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and was compared with those of oral cephems, i.e., cefteram pivoxil, cefpodoxime proxetil, cefdinir, and cefditoren pivoxil. Intranasal inoculation of 10(6) CFU of penicillin-susceptible or penicillin-resistant S. pneumoniae in the exponential growth phase induced pneumonia and bacteremia in ddY mice within 48 h. For the treatment of infections caused by the penicillin-susceptible strain the antibiotics were administered orally at 0.4, 2, and 10 mg/kg of body weight twice daily for 2 days beginning at 24 h after bacterial inoculation, and for the treatment of infections caused by a penicillin-resistant strain the antibiotics were administered at 2, 10, and 50 mg/kg twice daily for 2 days beginning at 24 h after bacterial inoculation. Among the antibiotics tested, CS-834 exhibited the most potent efficacy against both types of strains. Against infections caused by penicillin-susceptible S. pneumoniae, CS-834 at all doses significantly reduced the numbers of viable cells in both the lungs and blood. Cefpodoxime proxetil at all doses and cefteram pivoxil and cefditoren pivoxil at doses of 2 and 10 mg/kg showed comparable efficacies. Against infections caused by penicillin-resistant S. pneumoniae, CS-834 at doses of 10 and 50 mg/kg showed the most potent efficacy among the antibiotics tested, resulting in the maximum decrease in the numbers of viable cells in the lungs. Comparable efficacies were observed with cefteram pivoxil and cefpodoxime proxetil at doses of 50 mg/kg each. The concentration of CS-834 in the lungs and blood was higher than that of cefdinir and was lower than those of the other antibiotics tested, suggesting that the potent therapeutic efficacy of CS-834 reflects its strong activity against S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9449255      PMCID: PMC105450     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

2.  Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group.

Authors:  J S Spika; R R Facklam; B D Plikaytis; M J Oxtoby
Journal:  J Infect Dis       Date:  1991-06       Impact factor: 5.226

3.  Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Authors:  K Tateda; K Takashima; H Miyazaki; T Matsumoto; T Hatori; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.

Authors:  A Tamura; R Okamoto; T Yoshida; H Yamamoto; S Kondo; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Pneumococcal pneumonia. Diagnostic, epidemiologic, therapeutic and prophylactic considerations.

Authors:  R Austrian
Journal:  Chest       Date:  1986-11       Impact factor: 9.410

6.  Hospital study of adult community-acquired pneumonia.

Authors:  J T Macfarlane; R G Finch; M J Ward; A D Macrae
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

7.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

8.  Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.

Authors:  H C Neu; G Saha; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 9.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

10.  In vitro and in vivo antibacterial activities of T-2588, a new oral cephalosporin, compared with those of other oral beta-lactam antibiotics.

Authors:  S Okamoto; Y Hamana; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

View more
  5 in total

1.  In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.

Authors:  Tetsufumi Koga; Tomomi Abe; Harumi Inoue; Takashi Takenouchi; Akiko Kitayama; Tatsuhiko Yoshida; Nobuhisa Masuda; Chika Sugihara; Masayo Kakuta; Miyuki Nakagawa; Takahiro Shibayama; Yoko Matsushita; Takashi Hirota; Satoshi Ohya; Yukio Utsui; Takashi Fukuoka; Syogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 3.  Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents.

Authors:  H S Sader; A C Gales
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model.

Authors:  Fabio Cafini; Jose Yuste; Maria-Jose Giménez; David Sevillano; Lorenzo Aguilar; Luis Alou; Elisa Ramos-Sevillano; Martha Torrico; Natalia González; Ernesto García; Pilar Coronel; Jose Prieto
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 5.  Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

Authors:  Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.